Pfizer has garnered another US Food and Drug Administration biosimilar approval, receiving a nod from the agency for its Ruxience (rituximab-pvvr) rival to Genentech’s Rituxan original.
The approval marks the third oncology monoclonal antibody (mAb) biosimilar nod from the FDA this year for Pfizer, after Trazimera (trastuzumab-qyyp) in March (Also see "FDA Approves Pfizer's Trastuzumab Biosimilar" - Generics Bulletin, 12 March, 2019.) and Zirabev (bevacizumab-bvzr) at the end of June
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?